Treatment with the anti-cancer immune checkpoint inhibitor Tecentriq (atezolizumab) can cause cold agglutinin disease (CAD), a case report shows. The case was described in a letter to the editor, “Cold agglutinin disease as a new immune-related adverse event associated with anti-PD-L1s…
News
Scores of events are afoot worldwide to mark Feb. 28, Rare Disease Day 2019. The activities aim to raise awareness about rare diseases and the millions of people — estimates run as high as 350 million — they are thought to impact. Across countries, patients, caregivers and advocates will paint faces, wear…
The profile of patients with mixed autoimmune hemolytic anemia (MAIHA) must be carefully analyzed to facilitate diagnosis and disease management, a study says. The findings of the study, “Immunohematological and clinical characterizations of mixed autoimmune hemolytic anemia,” were published in the Asian Journal of Transfusion Science.
APL-2, Apellis Pharmaceuticals‘ investigational compound for the treatment of autoimmune hemolytic anemia (AIHA) and other complement system diseases, has received the designation of orphan drug from the U.S. Food and Drug Administration (FDA) for the treatment of AIHA. “This orphan drug designation represents an important recognition by…
A new case report described a man with altered body distribution of red blood cells (RBCs), which could have been caused by cold agglutinin disease (CAD). The study, “Abnormal Biodistribution of 99mTc Red Blood Cell Labeled Multi-Gated Acquisition Scan in the Presence of Suspected Cold Agglutinin Disease,”…
The U.S. Food and Drug Administration(FDA) is updating its 2015 draft guidelines for drug discovery in rare diseases, with new guidance on natural history— how disorders such as spinal muscle atrophy(SMA) run their course if untreated — the choice of “efficacy endpoints” in clinical trials, and how…
A case of simultaneous cryoglobulinemic vasculitis and cold agglutinin disease (CAD) was reported for the first time in a patient, according to Chinese researchers. The rare occurrence was described in the study, “Concomitant cryoglobulinemic vasculitis and cold agglutinin disease successfully treated with bortezomib: A case report,”…
Treatment with low-dose Rituxan can effectively treat patients with warm autoimmune hemolytic anemia (wAIHA) but higher doses may be more beneficial for patients with cold agglutinin disease (CAD), results from a 10-year retrospective study suggest. The study, “Low dose rituximab in autoimmune hemolytic anemia: ten years…
Despite being extremely rare, cold type autoimmune hemolytic anemia, or cold agglutinin disease (CAD), should be considered in patients with infectious mononucleosis, especially those who also have anemia, a case study reports. The case report, “Cold type autoimmune hemolytic anemia- a rare manifestation of infectious mononucleosis; serum ferritin as…
New therapies that target the complement pathway — a type of immune response that involves the production of antibodies — could help improve the treatment of cold agglutinin disease and other hemolytic anemias, a review study says. Clinical trials testing such therapies are recruiting patients. The article, “…
Recent Posts
- Oral therapy iptacopan eases anemia in CAD patients: Small trial
- When living with CAD, even a short trip can be a nightmare
- Real-world study confirms long-term safety of Enjaymo for CAD
- After months of fatigue, feeling better is what I want for Christmas
- Man’s case shows bacterial lung infection can ‘provoke’ clots, CAD
- Living with cold agglutinin disease involves cruel curveballs
- Gastric lymphoma found to be hidden cause of refractory CAD
- New CAD treatments, like reading progress, prove growth is possible
- ANX1502 proof-of-concept trial to wrap up next year, Annexon says
- What if Sadie Hawkins Day made me the doctor?